Exchange & Returns Information
Review Details
(36)
| Drug Type | Original |
|---|---|
| Active Ingredient | PEMBROLIZUMAB |
| Strength | 100MG |
| Manufacturer | MSD |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 3,342.00 | $ 3,342.00 |
$ 2,840.70
Apply ZARVY26 (-15%)
You save $ 501.30
|
||
| 2 BOXES - 2 VIALS | $ 3,296.00 |
1% $ 6,684.00
$ 6,592.00
|
$ 5,603.20
Apply ZARVY26 (-15%)
You save $ 988.80
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 3,247.33 |
3% $ 10,026.00
$ 9,742.00
|
$ 8,280.70
Apply ZARVY26 (-15%)
You save $ 1,461.30
|
Reference information will be available soon.
Keytruda 100 is a 100mg/4ml injectable formulation of pembrolizumab, a highly selective humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2). This blockade reinvigorates exhausted T-cells and restores antitumor immunity, making it a cornerstone of immune checkpoint inhibitor therapy. Pembrolizumab is used across a wide range of solid tumors and hematologic malignancies, either as monotherapy or in combination with chemotherapy, targeted agents, or other immunotherapies. It is administered via intravenous infusion and is dosed either every 3 or 6 weeks depending on the treatment protocol.
- AntiCancer Drugs > Non-Small Cell Lung Cancer (NSCLC) Used as first-line monotherapy in PD-L1 expressing NSCLC (TPS ≥1%) or in combination with platinum-based chemotherapy. Effective in both squamous and non-squamous subtypes. > Melanoma Approved for unresectable or metastatic melanoma and as adjuvant therapy following resection of stage III disease. Long-term responses have been observed. > Head and Neck Squamous Cell Carcinoma (HNSCC) Used in recurrent or metastatic HNSCC either as monotherapy or combined with platinum + 5-FU. PD-L1 CPS ≥1% is a key biomarker. > Urothelial Carcinoma (Bladder Cancer) Indicated for platinum-refractory metastatic disease or in combination with enfortumab vedotin. Also used for BCG-unresponsive NMIBC (non-muscle invasive bladder cancer). > Triple-Negative Breast Cancer (TNBC) Used in PD-L1 positive TNBC in combination with chemotherapy (e.g., paclitaxel) for advanced or early-stage neoadjuvant/adjuvant treatment. > Cervical Cancer Administered with chemotherapy ± bevacizumab for PD-L1 positive recurrent or metastatic disease. Also used in chemoradiotherapy regimens for locally advanced cases. > Endometrial Cancer Used as monotherapy in MSI-H/dMMR tumors or in combination with lenvatinib for pMMR or MSS tumors. > Gastric, Esophageal, Liver, Biliary Cancers Approved for various indications depending on PD-L1 expression, MSI/TMB status, or in combination strategies with platinum-based agents or atezolizumab.
- Blocks PD-1 receptor, restoring T-cell activity and immune surveillance - Promotes sustained antitumor responses in various advanced malignancies - Shows durable clinical benefit in both monotherapy and combination regimens - Biomarker-based efficacy: PD-L1, MSI-H, dMMR, TMB-H
1. Adult dose: → 200 mg IV every 3 weeks or 400 mg IV every 6 weeks → Administer over 30 minutes → Continue until disease progression, unacceptable toxicity, or up to 12–24 months depending on indication 2. Indications: → NSCLC (mono or combo) → Melanoma (unresectable, metastatic, or adjuvant) → HNSCC, TNBC, Cervical, Endometrial, Gastric, Esophageal, RCC, HCC, cSCC → Lymphomas: cHL, PMBCL → Rare tumors: Merkel cell carcinoma, biliary cancer → Biomarker-based use: MSI-H, TMB-H, PD-L1, dMMR tumors 3. Pediatric dose (≥12 years): → 2 mg/kg IV every 3 weeks (max 200 mg) → Duration: up to 24 months 4. Admin notes: → Administer first when given with other drugs → Monitor for immune-related adverse events (colitis, thyroiditis, pneumonitis, etc.)
Store at 2–8°C. Do not freeze or shake. Keep in original carton to protect from light. Use immediately after dilution; discard any unused portion.
Common: fatigue, nausea, rash, pruritus, diarrhea, arthralgia Immune-related AEs: pneumonitis, colitis, hepatitis, nephritis, endocrinopathies (thyroiditis, hypophysitis, adrenal insufficiency) Severe: infusion reactions, myocarditis, encephalitis Monitoring: LFTs, TSH/Free T4, renal function, glucose, cortisol, signs of immune AEs
The product was well packed with no damage or leakage.
Having multiple options made the checkout convenient.
The injection arrived without any problem.
I had a question about tracking, and the team updated me promptly. The order arrived intact soon after, exactly as expected.
I had a small concern about payment confirmation, but the support team answered within an hour. Delivery followed promptly, and everything arrived in excellent condition.
No combo deals available at the moment.
